

CD34 antibody [4H11(APG)] (FITC)

Cat. No. GTX18227

Host	Mouse
Clonality	Monoclonal
Isotype	IgG1
Applications	ICC/IF, FCM
Reactivity	Human

References (2)
 Package
 100 test

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
ICC/IF	Assay dependent
FCM	20 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension

Note : Do not need a permeabilization step.

Not tested in other applications.

Product Note

This antibody reacts with Class III epitope on CD34 (Mucosialin). The antibody 4H11[APG] completely blocks binding of Class II antibody QBEnd10 and Class III antibodies BIRMA K3 and 8G12 on KG1a cell line.

Properties

Form	Liquid
Buffer	PBS
Preservative	15mM Sodium azide
Storage	Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4°C. DO NOT FREEZE. Protect from light.
Concentration	Batch dependent (Please refer to the vial label for the specific concentration.)
Immunogen	Permanent human cell line derived from peripheral leucocytes of a patient suffering from chronic myeloid leukaemia.
Purification	Purified by size-exclusion chromatography
Conjugation	Fluorescein isothiocyanate (FITC) Wavelength

Note


For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our [website](#).

DATA IMAGES

**GTX18227 FCM Image**

Surface staining of Kg-1a human acute myelogenous leukemia cell line with anti-human CD34 [4H11[APG]] FITC (GTX18227). Total viable cells were used for analysis.

**GTX18227 ICC/IF Image**

Detection of CD34 in human chronic myeloid leukemia cell line MOLM-7 with anti-human CD34 [4H11[APG]]: PE (GTX18228).



For full product information, images and publications, please visit our [website](#).